USPTO Examiner LI BAO Q - Art Unit 1648

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17041147ADJUVANT AND VACCINE CONTAINING ADJUVANTDecember 2020June 2023Abandon3321NoNo
17121065COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS OF MHC CLASS I POSITIVE CELLS AND COUNTERING ANTI-CD47/SIRPA RESISTANCEDecember 2020June 2022Allow1810NoNo
17119548ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONISTDecember 2020April 2022Allow1611NoNo
17112055CHIMERIC HEPATITIS D VIRUS ANTIGEN AND HEPATITIS B VIRUS PRE S1 GENES FOR USE ALONE OR IN VACCINES CONTANING HEPATITIS B VIRUS GENESDecember 2020June 2022Allow1810YesNo
17106135Virus PurificationNovember 2020February 2022Allow1500YesNo
17100671TUMOR-SELECTIVE E1A AND E1B MUTANTSNovember 2020August 2022Allow2111NoNo
17095300GENETICALLY MODIFIED RECOMBINANT VACCINIA ANKARA (RMVA) VACCINES OF IMPROVED STABILITY AND METHODS OF PREPARATION THEREOFNovember 2020March 2024Allow4010NoNo
17093927Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human PrimatesNovember 2020September 2023Allow3421YesNo
17089527SMALLPOX VACCINE FOR CANCER TREATMENTNovember 2020November 2022Allow2421YesNo
17048714SELF-ATTENUATED PROPHYLACTIC AND THERAPEUTIC VACCINES AGAINST PATHOGENSOctober 2020April 2022Allow1810NoNo
17072136ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTUREOctober 2020May 2023Allow3130YesNo
17043192Antigenic Peptides For Prevention And Treatment Of CancerSeptember 2020November 2023Allow3701YesNo
17027295Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus ReceptorSeptember 2020July 2022Abandon2201NoNo
17025486AMH-INH-GNIH TRI-EXPRESSION GENE VACCINE OF IMPROVING FECUNDITY OF ANIMALS, PREPARATION METHOD AND APPLICATIONSeptember 2020March 2022Allow1810NoNo
17014028IMMUNOTHERAPEUTIC COMPOSITIONSSeptember 2020January 2023Abandon2821NoNo
17004583RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGSAugust 2020January 2023Allow2931YesNo
17003818METHODS AND MATERIALS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONSAugust 2020March 2022Allow1910NoNo
17000377VACCINE COMPOSITION AND METHOD OF PREVENTING PORCINE EPIDEMIC DIARRHEA VIRUS INFECTION IN SWINEAugust 2020May 2022Allow2111YesNo
16997552COMBINATION THERAPY FOR TREATMENT OF BRAIN CANCERSAugust 2020April 2021Allow810YesNo
16993856HA BINDING AGENTSAugust 2020February 2024Allow4221YesNo
16947694TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONSAugust 2020February 2022Allow1810NoNo
16969423IMMUNOGENIC COMPOSITION AND VACCINE FOR GENERATING AN IMMUNE RESPONSE TO NOROVIRUSAugust 2020December 2022Allow2821YesNo
16966726A NOVEL VACCINE ADJUVANTJuly 2020May 2023Allow3331YesNo
16937801COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSEJuly 2020February 2022Allow1910NoNo
16938707Half-life optimized linker compositionJuly 2020February 2021Allow610YesNo
16937171COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSEJuly 2020February 2022Allow1910NoNo
16935813COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSEJuly 2020February 2022Allow1810NoNo
16963718BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINEJuly 2020February 2022Allow1910YesNo
16927086ZIKA VIRUS PURIFICATIONJuly 2020July 2022Allow2411YesNo
16926704RAPID AND PROLONGED IMMUNOGIC THERAPEUTICJuly 2020January 2021Allow610YesNo
16926703RAPID AND PROLONGED IMMUNOGIC THERAPEUTICJuly 2020April 2021Allow920YesNo
16960869IMMUNE MODULATIONJuly 2020May 2023Abandon3421NoNo
16921959Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosisJuly 2020December 2021Allow1720NoNo
16921113DIAGNOSTIC AND TREATMENT FOR COVID-19July 2020April 2022Allow2131YesNo
16917899ALPHAHERPESVIRUS GLYCOPROTEIN D-ENCODING NUCLEIC ACID CONSTRUCTS AND METHODSJune 2020May 2021Allow1120YesNo
16912886HIV Binding AgentsJune 2020June 2022Abandon2310YesNo
16911171MODIFIED VIRAL VECTORS AND METHODS OF MAKING AND USING THE SAMEJune 2020May 2023Allow3511YesNo
16954835VACCINES WITH ENHANCED IMMUNOGENICITY, LOW ALLERGENICITY AND REACTOGENICITYJune 2020October 2021Allow1611NoNo
16902068CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASEJune 2020September 2021Allow1500YesNo
16900070NOVEL ADJUVANT FOR ANIMAL AND HUMAN VACCINESJune 2020May 2023Allow3511YesNo
16772194HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONSJune 2020August 2023Allow3921YesNo
16896574METHOD AND SYSTEM FOR INACTIVATING VIRUS INFECTIVITY FOR PRODUCING LIVE-ATTENUATED VACCINESJune 2020March 2022Allow2110YesNo
16768844VECTOR FOR THE PRODUCTION OF AAV PARTICLESJune 2020February 2023Allow3310NoNo
16768489IMMUNO-MODULATED REPLICATION-EFFICIENT VACCINIA VIRUS STRAINMay 2020December 2022Allow3010NoNo
16768057SYNPIII, A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN RETINAL PIGMENT EPITHELIUMMay 2020October 2022Allow2910NoNo
16764541PASYLATED VEGFR/PDGFR FUSION PROTEINS AND THEIR USE IN THERAPYMay 2020September 2022Allow2810NoNo
16874431DUAL-MOLECULAR DNA VACCINE COMPOSED OF A VIRAL ANTIGEN AND AN IMMUNE COSTIMULATORMay 2020May 2022Abandon2401NoNo
15930966IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOFMay 2020May 2023Allow3611NoNo
16870874METHODS, SYSTEMS, AND DEVICES FOR MEASURING IMMUNITY TO SARS-COV-2May 2020October 2022Abandon3001NoNo
16867750CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYSMay 2020October 2022Abandon2920NoNo
16868243NON-NEUROINVASIVE VIRUSES AND USES THEREOFMay 2020May 2022Allow2411NoNo
16868246Non-Neuroinvasive Viruses and Uses ThereofMay 2020February 2022Allow2110NoNo
16861758REPLICATION-DEFECTIVE ARENAVIRUS VECTORSApril 2020March 2022Allow2310YesNo
16759584TAU PEPTIDE IMMUNOGEN CONSTRUCTSApril 2020February 2023Allow3310YesNo
16855115APOPTOTIC UPREGULATION BY MYXOMA VIRUS EXPRESSING WALLEYE DERMAL SARCOMA VIRUS ORFCApril 2020January 2023Allow3311NoNo
16854703SINGLE-DOMAIN VHH ANTIBODIES DIRECTED TO NOROVIRUS GI.1 AND GII.4 AND THEIR USEApril 2020January 2022Allow2110YesNo
16843439COMPOSITIONS AND METHODS FOR STABILIZING ALPHAVIRUSES WITH IMPROVED FORMULATIONSApril 2020May 2022Abandon2510NoNo
16840760VIRUS PURIFICATIONApril 2020March 2022Allow2410NoNo
16836515Improved Compositions And Methods For Viral Delivery Of Neoepitopes And Uses ThereofMarch 2020April 2022Allow2411YesNo
16830461METHODS OF PREVENTING SECONDARY INFECTIONSMarch 2020March 2022Allow2411YesNo
16648475MOLECULAR GRAFTING OF COMPLEX, BROADLY NEUTRALIZING ANTIBODY EPITOPESMarch 2020March 2022Abandon2310NoNo
16648439SYNTHETIC HEMAGGLUTININ AS UNIVERSAL VACCINE AGAINST INFECTION BY TYPE B INFLUENZA VIRUSES (IBV)March 2020May 2022Allow2630YesNo
16822354COMPOSITIONS, METHODS AND KITS FOR ELICITING AN IMMUNE RESPONSEMarch 2020March 2022Allow2421YesNo
16816320Adeno-associated viral (AAV) vectors useful for transducing adipose tissueMarch 2020December 2022Allow3310NoNo
16645646METHODS AND COMPOSITIONS TO ENHANCE THE IMMUNOGENICITY OF TUMORSMarch 2020June 2023Abandon3911NoNo
16645020Combination Therapies of Hepatitis B Virus (HBV)-infected individuals using Parapoxvirus Ovis (PPVO) and at Least one Further Antiviral DrugMarch 2020February 2024Abandon4731YesNo
16808701METHODS AND COMPOSITIONS FOR TREATING GLIOMA AND MEDULLOBLASTOMA BRAIN TUMORS USING THE ZIKA VIRUSMarch 2020January 2022Allow2210NoNo
16799090MODIFIED ONCOLYTIC VIRUSFebruary 2020November 2021Allow2020YesNo
16641236Combination Therapy for Treating Cancer with an Intravenous Administration of a Recombinant MVA and an AntibodyFebruary 2020October 2021Allow2011YesNo
16795433MULTI-VALENT HEPATITIS B VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOFFebruary 2020August 2022Allow3011YesNo
16790841COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT AAVFebruary 2020March 2023Allow3711NoNo
16790114REOVIRUSES HAVING MODIFIED SEQUENCESFebruary 2020December 2021Allow2211NoNo
16786134RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOFFebruary 2020February 2023Allow3620YesNo
16782268POXVIRAL VACCINESFebruary 2020November 2021Allow2111NoNo
16747433SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPYJanuary 2020April 2021Allow1500YesNo
16740203ONCOLYTIC VIRUS STRAINJanuary 2020October 2021Allow2121YesNo
16736327MULTI-VALENT HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN BINDING MOLECULES AND USES THEREOFJanuary 2020August 2021Allow1910NoNo
16727561NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODYDecember 2019December 2021Allow2411NoNo
16626281CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSESDecember 2019November 2021Allow2311YesNo
16717946HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINEDecember 2019July 2021Allow1910YesNo
16704669USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFORDecember 2019November 2021Allow2310NoNo
16702764VIRUS PURIFICATIONDecember 2019August 2021Allow2010YesNo
16617889A METHOD TO CREATE PERSONALIZED CANINE CANCER VACCINESNovember 2019May 2022Allow3011YesNo
16662096NOVEL IMMUNIZATION AGENTS AND METHODS OF USEOctober 2019June 2022Allow3221YesNo
16604343A METHOD FOR PREDICTING TIME-TO-VIRAL CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION UNDER DIRECT ACTING ANTIVIRAL (DAA) THERAPYOctober 2019March 2023Abandon4101NoNo
16593658COMPOSITIONS AND METHODS FOR INDUCING PROTECTIVE IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTIONOctober 2019August 2021Allow2310YesNo
16551787BACULOVIRUS-BASED PRODUCTION OF BIOPHARMACEUTICALS FREE OF CONTAMINATING BACULOVIRAL VIRIONSAugust 2019September 2021Allow2411YesNo
16547059PHAGE COMPOSITION AND USE THEREOF IN INACTIVING ANTIBIOTIC RESISTANCE PATHOGENIC BACTERIAAugust 2019July 2022Abandon3520YesNo
16546749COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACIDAugust 2019May 2021Allow2120YesNo
16547051PHAGE AND USE THEREOF IN SOIL REMEDIATIONAugust 2019October 2021Allow2621YesNo
16538664METHODS FOR PRODUCING PREPARATIONS OF RECOMBINANT AAV VIRIONS SUBSTANTIALLY FREE OF EMPTY CAPSIDSAugust 2019August 2021Allow2410NoNo
16530786COMPOSITIONS, METHODS AND USES FOR IMPROVED HUMAN PAPILLOMA VIRUS CONSTRUCTSAugust 2019July 2021Allow2310YesNo
16522371METHODS AND COMPOSITIONS RELATING TO VIRAL LATENCYJuly 2019February 2021Allow1900YesNo
16520467COMPOSITIONS AND METHODS FOR DETECTING HUMAN PAPILLOMAVIRUS NUCLEIC ACIDJuly 2019March 2021Allow2010NoNo
16505168PURIFICATION OF HERPES VIRUSJuly 2019September 2021Allow2620YesNo
16452783INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENEJune 2019September 2021Allow2720YesNo
16447209RECOMBINANT B11 BACTERIOPHAGES AND USES THEREOFJune 2019September 2020Allow1500YesNo
16439604RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROMJune 2019September 2021Abandon2711NoNo
16431769ANTIBODY, COMPOSITE, DETECTION DEVICE AND METHOD USING SAMEJune 2019September 2020Allow1500NoNo
16423839METHODS AND COMPOSITIONS TO INCREASE IMMUNE RESPONSE TO VACCINESMay 2019April 2021Allow2311NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, BAO Q.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
4
(66.7%)
Examiner Reversed
2
(33.3%)
Reversal Percentile
50.3%
Higher than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
82
Allowed After Appeal Filing
14
(17.1%)
Not Allowed After Appeal Filing
68
(82.9%)
Filing Benefit Percentile
21.9%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LI, BAO Q - Prosecution Strategy Guide

Executive Summary

Examiner LI, BAO Q works in Art Unit 1648 and has examined 805 patent applications in our dataset. With an allowance rate of 59.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner LI, BAO Q's allowance rate of 59.6% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LI, BAO Q receive 1.99 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LI, BAO Q is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.4% benefit to allowance rate for applications examined by LI, BAO Q. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.1% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 46.3% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 127.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 85.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.3% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.